These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33489708)

  • 1. Limb arteriolar vasculitis induced by pembrolizumab plus chemotherapy in a patient with lung cancer.
    Takada K; Hamatake M; Kohashi K; Shimamatsu S; Hirai F; Ohmori S; Tagawa T; Mori M
    Int Cancer Conf J; 2021 Jan; 10(1):83-86. PubMed ID: 33489708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report.
    Hines J; Daily E; Pham AK; Shea CR; Nadeem U; Husain AN; Stadler WM; Reid P
    J Med Case Rep; 2021 Mar; 15(1):124. PubMed ID: 33736690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multidisciplinary approach to treating a unique case of recurrent metastatic thymic carcinoma: case report.
    Wang C; Erick Elkowitz D; Esposito MJ; Shah RD; Tannous H; Barilla-Labarca ML; Seetharamu N
    Ther Adv Rare Dis; 2023; 4():26330040231190661. PubMed ID: 37576433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypothyroidism and hypopituitarism as immune-related adverse events due to lenvatinib plus pembrolizumab therapy in the immediate postoperative period after laparoscopic hepatectomy for liver metastases from gastric cancer: a case report.
    Sasaki K; Kobayashi S; Kudo M; Sugimoto M; Takahashi S; Nakamura Y; Kawazoe A; Shitara K; Kinoshita T; Gotohda N
    Surg Case Rep; 2021 Dec; 7(1):267. PubMed ID: 34928436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case of panuveitis and retinal vasculitis associated with pembrolizumab therapy for metastatic lung cancer.
    Kim KW; Kusuhara S; Tachihara M; Mimura C; Matsumiya W; Nakamura M
    Am J Ophthalmol Case Rep; 2021 Jun; 22():101072. PubMed ID: 33796799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete response in a patient with lung cancer suffering from three pembrolizumab-induced immune-related adverse events including retinal vasculitis.
    Mimura C; Tachihara M; Kusuhara S; Fukuoka H; Nishimura Y
    Respirol Case Rep; 2021 Apr; 9(4):e00730. PubMed ID: 33732464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab-induced severe oral mucositis in a patient with squamous cell carcinoma of the lung: A case study.
    Yoon SY; Han JJ; Baek SK; Kim HJ; Maeng CH
    Lung Cancer; 2020 Sep; 147():21-25. PubMed ID: 32652370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer.
    Baroz AR; Mambetsariev I; Fricke J; Pharaon R; Tan T; Kidambi T; Sandhu KS; Koczywas M; Salgia R
    Cureus; 2021 Jul; 13(7):e16266. PubMed ID: 34377604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Case of Lung Adenocarcinoma with Long-Term Response after Late-Onset Pembrolizumab-Induced Acute Adrenal Insufficiency.
    Sonehara K; Tateishi K; Hirabayashi T; Araki T; Ikuyama Y; Machida R; Hanaoka M
    Case Rep Oncol; 2021; 14(1):1-7. PubMed ID: 33613234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
    Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
    J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypothyroidism With ACTH Deficiency During Pembrolizumab Therapy for Lung Cancer: Case Report and Literature Review.
    Hashinokuchi A; Haro A; Minagawa R; Haruta Y; Kawano H; Suehiro T; Sugimachi K
    Cancer Diagn Progn; 2023; 3(4):498-503. PubMed ID: 37405219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Successful treatment of Guillain-Barré syndrome-like acute inflammatory demyelinating polyneuropathy caused by pembrolizumab with a combination of corticosteroid and immunoglobulins: a case report].
    Hashimoto R; Ueda T; Tsuji Y; Otsuka Y; Sekiguchi K; Matsumoto R
    Rinsho Shinkeigaku; 2020 Nov; 60(11):773-777. PubMed ID: 33115993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab-induced aseptic meningitis in a patient with non-small cell lung cancer: A case report and literature review of aseptic meningitis as an immune-related adverse event.
    Inui G; Funaki Y; Makino H; Touge H; Arai K; Kuroda K; Hirayama Y; Kato R; Nonaka T; Yamane K; Teruya Y; Sueda Y; Sakamoto T; Yamaguchi K; Kodani M; Kawase S; Umekita Y; Horie Y; Nosaka K; Yamasaki A
    Mol Clin Oncol; 2022 Jul; 17(1):120. PubMed ID: 35747596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Case of Nonsmall-Cell Lung Cancer with Anaphylaxis after 41 Courses of Pembrolizumab along with Adrenal Insufficiency as an Immune-Related Adverse Event.
    Nakamura T; Imai R; Nishimura N
    Case Rep Oncol; 2022; 15(3):804-808. PubMed ID: 36825102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Case of Guillain-Barré Syndrome and Stevens-Johnson Syndrome/Toxic Epidermal Necrosis Overlap After Pembrolizumab Treatment.
    Oguri T; Sasada S; Shimizu S; Shigematsu R; Tsuchiya Y; Ishioka K; Takahashi S; Oki K; Kimura Y; Seki R; Hirose S; Nakamura M
    J Investig Med High Impact Case Rep; 2021; 9():23247096211037462. PubMed ID: 34344201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
    Beck TN; Kudinov AE; Dulaimi E; Boumber Y
    BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab-induced secondary adrenal insufficiency due to adrenocorticotrophic hormone deficiency in a patient with non-small-cell lung carcinoma: a case report.
    Fujimiya T; Azuma K; Togashi Y; Kuwata K; Unezaki S; Takeuchi H
    J Pharm Health Care Sci; 2024 Feb; 10(1):10. PubMed ID: 38365819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report.
    Sugano T; Seike M; Funasaka Y; Yoshida M; Takayama R; Okamura K; Nakanishi A; Tanaka T; Takeuchi S; Noro R; Minegishi Y; Kubota K; Saeki H; Gemma A
    J Immunother Cancer; 2019 Feb; 7(1):59. PubMed ID: 30813943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab-Induced Immune-Mediated Glossitis.
    Alias A; Hall JA; Kulkarni P; Gowan AC
    Cureus; 2022 Jan; 14(1):e21708. PubMed ID: 35242475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-related adverse events caused by treatment with pembrolizumab in a patient with lung cancer who infected influenza virus.
    Takemura M; Motegi M; Kuroiwa Y; Itai M; Taguchi K; Umetsu K; Uchida M; Kounoc S; Sato M; Masubuchi H; Yamaguchi A; Yamaguchi K; Ikeda K; Nakagawa J; Maeno T
    Respir Med Case Rep; 2021; 32():101361. PubMed ID: 33643837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.